BIOMAT Database Logo BIOMAT Database Logo

Induction of vascular endothelial growth factor expression by prostaglandin E2 and E1 in osteoblasts. 1994

S Harada, and J A Nagy, and K A Sullivan, and K A Thomas, and N Endo, and G A Rodan, and S B Rodan
Department of Bone Biology and Osteoporosis Research, Merck Research Laboratories, West Point, Pennsylvania 19486.

PGE1 and PGE2 are potent stimulators of bone formation. Osteogenesis is strongly dependent on angiogenesis. Vascular endothelial growth factor (VEFG), a secreted endothelial cell-specific mitogen, has been implicated in physiological and pathological angiogenesis. The aim of this study was to examine the possible role of VEGF in PG stimulation of bone formation. We found that in rat calvaria-derived osteoblast-enriched cells and in the osteoblastic RCT-3 cell line PGE2 and E1 increased VEGF mRNA and protein levels. The increased expression of VEGF mRNA produced by PGE2 was rapid (maximal at 1 h), transient (declined by 3 h), potentiated by cycloheximide, and abolished by actinomycin D. PGE2 had no effect on VEGF mRNA stability, suggesting transcriptional regulation of VEGF expression by PGF2. Rp-cAMP, a cAMP antagonist, suppressed VEGF mRNA induced by PGE2, indicating cAMP mediation. The upregulation of VEGF expression by PGE2 in the preosteoblastic RCT-1 cells was potentiated by treatment with retinoic acid, which induces the differentiation of these cells. The upregulation of VEGF mRNA by PGE2 was inhibited by dexamethasone treatment. In addition, Northern blot analysis showed that VEGF mRNA is expressed in adult rat tibia. In summary, we documented, for the first time, the expression of VEGF in osteoblasts and in bone tissue. Stimulation of VEGF expression by PGs and its suppression by glucocorticoids, which, respectively, stimulate and suppress bone formation, strongly implicate the involvement of VEGF in bone metabolism.

UI MeSH Term Description Entries
D008222 Lymphokines Soluble protein factors generated by activated lymphocytes that affect other cells, primarily those involved in cellular immunity. Lymphocyte Mediators,Mediators, Lymphocyte
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D010006 Osteoblasts Bone-forming cells which secrete an EXTRACELLULAR MATRIX. HYDROXYAPATITE crystals are then deposited into the matrix to form bone. Osteoblast
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003513 Cycloheximide Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis. Actidione,Cicloheximide
D003609 Dactinomycin A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015) Actinomycin,Actinomycin D,Meractinomycin,Cosmegen,Cosmegen Lyovac,Lyovac-Cosmegen,Lyovac Cosmegen,Lyovac, Cosmegen,LyovacCosmegen
D003907 Dexamethasone An anti-inflammatory 9-fluoro-glucocorticoid. Hexadecadrol,Decaject,Decaject-L.A.,Decameth,Decaspray,Dexasone,Dexpak,Hexadrol,Maxidex,Methylfluorprednisolone,Millicorten,Oradexon,Decaject L.A.
D005260 Female Females
D000242 Cyclic AMP An adenine nucleotide containing one phosphate group which is esterified to both the 3'- and 5'-positions of the sugar moiety. It is a second messenger and a key intracellular regulator, functioning as a mediator of activity for a number of hormones, including epinephrine, glucagon, and ACTH. Adenosine Cyclic 3',5'-Monophosphate,Adenosine Cyclic 3,5 Monophosphate,Adenosine Cyclic Monophosphate,Adenosine Cyclic-3',5'-Monophosphate,Cyclic AMP, (R)-Isomer,Cyclic AMP, Disodium Salt,Cyclic AMP, Monoammonium Salt,Cyclic AMP, Monopotassium Salt,Cyclic AMP, Monosodium Salt,Cyclic AMP, Sodium Salt,3',5'-Monophosphate, Adenosine Cyclic,AMP, Cyclic,Adenosine Cyclic 3',5' Monophosphate,Cyclic 3',5'-Monophosphate, Adenosine,Cyclic Monophosphate, Adenosine,Cyclic-3',5'-Monophosphate, Adenosine,Monophosphate, Adenosine Cyclic

Related Publications

S Harada, and J A Nagy, and K A Sullivan, and K A Thomas, and N Endo, and G A Rodan, and S B Rodan
Expression and regulation of vascular endothelial growth factor in osteoblasts.
April 1995, Clinical orthopaedics and related research,
S Harada, and J A Nagy, and K A Sullivan, and K A Thomas, and N Endo, and G A Rodan, and S B Rodan
Transforming growth factor-beta1 modulates the expression of vascular endothelial growth factor by osteoblasts.
October 1999, The American journal of physiology,
S Harada, and J A Nagy, and K A Sullivan, and K A Thomas, and N Endo, and G A Rodan, and S B Rodan
Wnt3a upregulates prostaglandin F2α-stimulated vascular endothelial growth factor synthesis in osteoblasts.
August 2012, Molecular medicine reports,
S Harada, and J A Nagy, and K A Sullivan, and K A Thomas, and N Endo, and G A Rodan, and S B Rodan
Tiludronate inhibits prostaglandin F2alpha-induced vascular endothelial growth factor synthesis in osteoblasts.
May 2005, Molecular and cellular endocrinology,
S Harada, and J A Nagy, and K A Sullivan, and K A Thomas, and N Endo, and G A Rodan, and S B Rodan
Minodronate suppresses prostaglandin F2alpha-induced vascular endothelial growth factor synthesis in osteoblasts.
March 2006, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
S Harada, and J A Nagy, and K A Sullivan, and K A Thomas, and N Endo, and G A Rodan, and S B Rodan
Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Müller cells.
March 1998, Investigative ophthalmology & visual science,
S Harada, and J A Nagy, and K A Sullivan, and K A Thomas, and N Endo, and G A Rodan, and S B Rodan
Relationship between prostaglandin E2 and vascular endothelial growth factor (VEGF) in angiogenesis in human vascular endothelial cells.
June 2006, Vascular pharmacology,
S Harada, and J A Nagy, and K A Sullivan, and K A Thomas, and N Endo, and G A Rodan, and S B Rodan
Human vascular endothelial growth factor cDNA cloning and expression in osteoblasts.
January 2001, Journal of Tongji Medical University = Tong ji yi ke da xue xue bao,
S Harada, and J A Nagy, and K A Sullivan, and K A Thomas, and N Endo, and G A Rodan, and S B Rodan
Expression of vascular endothelial growth factor in normal, osteoarthritic and osteoporotic osteoblasts.
February 2013, Clinical and experimental medicine,
S Harada, and J A Nagy, and K A Sullivan, and K A Thomas, and N Endo, and G A Rodan, and S B Rodan
Prostaglandin E2 induces degranulation-independent production of vascular endothelial growth factor by human mast cells.
January 2004, Journal of immunology (Baltimore, Md. : 1950),
Copied contents to your clipboard!